EU awards FET-Proactive grant to Wouter Roos and seven other European groups
In the framework of H2020 the FET-Proactive project VIRUSCAN has been awarded to a consortium of 8 European research groups at technological centres, universities, hospitals and companies in the Netherlands, Germany, France, Spain and Greece. In the Netherlands research groups at TNO and at the Rijksuniversiteit Groningen (RUG) are being funded. The group at the RUG is led by Wouter Roos who is looking forward to cooperate with the other groups in this challenging project. Viruscan will be supported by the EU with 7 M€ of which 0.6 M€ will be for the RUG.

In the Viruscan project Optomechanics will be applied in Virology. Lately, optomechanics has served to fundamental advancements in physics, from gravitational wave detection to the study of mechanical quantum ground states but it has not yet delivered its full applicability potential.
The current project aims to apply frontier advancements in optomechanics to the biosensing and diagnostic fields and to create a new interdisciplinary research community with the goal to advance optomechanics, nanoelectromechanics, atomic force microscopy, native mass spectrometry and biophysics towards clinical applications.
Viruscan aims to provide novel technology capable of identifying viral particles and to assess their infective potential through the characterization of two physical parameters: mass and stiffness. Stiffness of viral particles has been recently known to act as a regulator of their infectivity at different stages of the virus life cycle. In parallel, advancements in nanoelectromechanical systems have recently demonstrated that stiffness and mass information from nanoscale adsorbates can be disentangled. Targeting intrinsic physical properties of viral particles will allow developing an open platform that will tackle any virus and their mutations.

The joint research and development project will have impact at multiple levels and aims at the following: Providing a personalized treatment to the patients, reducing the use of non-effective antibiotics, increasing safety in blood transfusions, allowing a quick and trustworthy response to emergency situations (e.g. recent EBOLA in West Africa and the ZIKA in Brazil), reducing the spread of viral infections, reducing costs per analysis and screening of a wide range of pathogens.
More info? Contact Prof. Wouter Roos.
Last modified: | 16 March 2017 11.16 a.m. |
More news
-
03 April 2025
IMChip and MimeCure in top 10 of the national Academic Startup Competition
Prof. Tamalika Banerjee’s startup IMChip and Prof. Erik Frijlink and Dr. Luke van der Koog’s startup MimeCure have made it into the top 10 of the national Academic Startup Competition.
-
01 April 2025
NSC’s electoral reform plan may have unwanted consequences
The new voting system, proposed by minister Uitermark, could jeopardize the fundamental principle of proportional representation, says Davide Grossi, Professor of Collective Decision Making and Computation at the University of Groningen
-
01 April 2025
'Diversity leads to better science'
In addition to her biological research on ageing, Hannah Dugdale also studies disparities relating to diversity in science. Thanks to the latter, she is one of the two 2024 laureates of the Athena Award, an NWO prize for successful and inspiring...